
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Lentiglobin
Therapeutic Area : Genetic Disease
Study Phase : Phase I/ Phase II
Sponsor : Bluebird Bio
Deal Size : Undisclosed
Deal Type : Agreement
Details : The two subsidiaries, Hitachi Chemical Advanced Therapeutics Solutions (HCATS) and Apceth Biopharma, will be in charge of late-clinical development and manufacturing of LentiGlobin at facilities in Germany (Apceth) and the U.S. (HCATS).
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
May 21, 2020
Lead Product(s) : Lentiglobin
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Sponsor : Bluebird Bio
Deal Size : Undisclosed
Deal Type : Agreement
